Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Alopecia × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2 Lymphoid 1

Conditions

Lymphoma 114 Leukemia, Lymphocytic, Chronic, B-Cell 83 Precursor Cell Lymphoblastic Leukemia-Lymphoma 75 Lymphoma, Non-Hodgkin 74 Lymphoma, Follicular 66 Lymphoma, Large B-Cell, Diffuse 64 Leukemia 52 Lymphoma, Mantle-Cell 45 Burkitt Lymphoma 42 Hodgkin Disease 39 Lymphoma, B-Cell, Marginal Zone 36 Leukemia, Myeloid, Acute 35 Lymphoma, B-Cell 34 Recurrence 32 Lymphoma, T-Cell, Cutaneous 23 Mycosis Fungoides 22 Myelodysplastic Syndromes 21 Waldenstrom Macroglobulinemia 19 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19 Multiple Myeloma 19 Lymphoma, Large-Cell, Immunoblastic 18 Lymphoma, Large-Cell, Anaplastic 18 Neoplasms 17 Sezary Syndrome 16 Hematologic Neoplasms 15 Lymphoma, Extranodal NK-T-Cell 14 Myeloproliferative Disorders 13 Congenital Abnormalities 12 Leukemia, Myeloid, Accelerated Phase 11 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00746980 2016-06-14

Efalizumab in the Treatment of Alopecia, Phase II

Northwestern University

Phase 2 Withdrawn

Alopecia, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡